UCB Presents New Data on Impact and Burden of Epilepsy at 2024 American Epilepsy Society (AES) Annual Meeting | PR Newswire [Video]

• Results of a social media listening study of women of childbearing age with epilepsy underscore the need for HCPs to provide relevant information at critical time points to support shared decision-making²
• A quality-of-life survey administered to caregivers of individuals with developmental and epileptic encephalopathies (DEEs) suggests improved understanding of caregiver definitions of normal and disruptive experiences can help researchers prioritize areas of focus to improve outcomes³
• Study shows prolonged seizures are a key driver in worsening quality of life for people with epilepsy and their caregivers⁴
• Pharmacokinetic data from Phase 1 study shows alprazolam administration via the Staccato® hand-held device is an efficient delivery route currently being studied for stereotypical prolonged seizures⁵
• New efficacy data on FINTEPLA® (fenfluramine) as a treatment for seizures associated with Lennox-Gastaut syndrome (LGS)⁶

, /PRNewswire/ — UCB, a global biopharmaceutical company, today announced data being presented at the American Epilepsy Society (AES) Annual …